Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

Launched by KEYMED BIOSCIENCES CO.LTD · Dec 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called CM310 to understand how it moves and behaves in the body of healthy adults. The trial is in its early phase and will involve participants who are between 20 and 45 years old, and only males can take part. To join, people must be in good health, meaning they should not have any serious medical conditions or be taking medications within 28 days before the trial starts.

If someone is eligible and decides to participate, they will be asked to sign a consent form to confirm they understand what the study involves. During the trial, participants will receive CM310 and provide information about how their bodies process the drug. It's important to note that the study is not yet recruiting participants, so there will be more information available later about how to join if someone is interested.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 20 years ≤ age ≤ 45 years.
• • Voluntarily participate in the study and sign the ICF.
• • Have the ability to understand the study.
• Exclusion Criteria:
• • With history of chronic or serious illness.
• • With any medication within 28 days prior to administration;
• • Plan to undergo surgery during the research period;
• • With any situations unsuitable to participate in this study.